Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Opus Genetics (Nasdaq: IRD), a clinical-stage ophthalmic biopharmaceutical company, has announced the approval of equity awards as inducement grants to two new employees by its Board's independent members. The awards, approved under the Company's 2021 Inducement Plan and in accordance with Nasdaq Listing rule 635(c)(4), consist of options to purchase 205,742 shares of common stock.
The options were granted on March 13, 2025, with an exercise price of $0.93 per share, matching the closing price on the grant date. The vesting schedule spans four years, with 25% vesting after the first year and the remaining 75% vesting in monthly or quarterly installments thereafter, subject to certain acceleration or forfeiture conditions.
Opus Genetics (Nasdaq: IRD), un'azienda biofarmaceutica oftalmica in fase clinica, ha annunciato l'approvazione di premi azionari come incentivi per due nuovi dipendenti da parte dei membri indipendenti del Consiglio. I premi, approvati nell'ambito del Piano di Incentivazione 2021 della Societ脿 e in conformit脿 con la regola di quotazione Nasdaq 635(c)(4), consistono in opzioni per acquistare 205.742 azioni di azioni ordinarie.
Le opzioni sono state concesse il 13 marzo 2025, con un prezzo di esercizio di 0,93 $ per azione, corrispondente al prezzo di chiusura nella data di concessione. Il piano di maturazione si estende per quattro anni, con un 25% che matura dopo il primo anno e il restante 75% che matura in rate mensili o trimestrali successivamente, soggetto a determinate condizioni di accelerazione o di perdita.
Opus Genetics (Nasdaq: IRD), una empresa biofarmac茅utica oft谩lmica en etapa cl铆nica, ha anunciado la aprobaci贸n de premios de acciones como incentivos para dos nuevos empleados por parte de los miembros independientes de su Junta. Los premios, aprobados bajo el Plan de Incentivos 2021 de la Compa帽铆a y de acuerdo con la regla de cotizaci贸n 635(c)(4) de Nasdaq, consisten en opciones para comprar 205,742 acciones de acciones ordinarias.
Las opciones se otorgaron el 13 de marzo de 2025, con un precio de ejercicio de $0.93 por acci贸n, igualando el precio de cierre en la fecha de concesi贸n. El calendario de adquisici贸n se extiende por cuatro a帽os, con un 25% que se adquiere despu茅s del primer a帽o y el restante 75% que se adquiere en cuotas mensuales o trimestrales posteriormente, sujeto a ciertas condiciones de aceleraci贸n o p茅rdida.
Opus Genetics (Nasdaq: IRD)電� 鞛勳儊 雼硠鞚� 鞎堦臣 靸濍獏瓿淀暀 須岇偓搿�, 鞚挫偓須岇潣 霃呺鞝侅澑 甑劚鞗愳棎 鞚橅暣 霊� 氇呾潣 鞁犾瀰 歆侅洂鞐愱矊 鞙犾澑 氤挫儊鞙茧靹� 欤检嫕 氤挫儊鞚� 鞀轨澑頄堧嫟瓿� 氚滍憸頄堨姷雼堧嫟. 鞚� 氤挫儊鞚� 須岇偓鞚� 2021雲� 鞙犾澑 瓿勴殟鞐� 霐半澕 鞀轨澑霅橃棃鞙茧┌, Nasdaq 靸侅灔 攴滌箼 635(c)(4)鞐� 霐半澕 205,742欤�鞚� 氤错喌欤茧ゼ 甑Г頃� 靾� 鞛堧姅 鞓奠厴鞙茧 甑劚霅╇媹雼�.
鞓奠厴鞚赌 2025雲� 3鞗� 13鞚�鞐� 攵�鞐悩鞐堨溂氅�, 頄夓偓 臧�瓴╈潃 欤茧嫻 $0.93搿�, 攵�鞐澕鞚� 膦呹皜鞕� 鞚检箻頃╇媹雼�. 甓岆Μ 頇曥爼 鞚检爼鞚� 4雲勳溂搿�, 觳� 頃挫棎 25%臧� 頇曥爼霅橂┌, 雮橂ǜ歆� 75%電� 鞚错泟 毵れ洈 霕愲姅 攵勱赴氤� 頃犽秬搿� 頇曥爼霅橂┌, 韸轨爼 臧�靻� 霕愲姅 氇办垬 臁瓣贝鞐� 霐半澕 雼澕歆� 靾� 鞛堨姷雼堧嫟.
Opus Genetics (Nasdaq: IRD), une entreprise biopharmaceutique ophtalmique en phase clinique, a annonc茅 l'approbation de r茅compenses en actions comme incitations pour deux nouveaux employ茅s par les membres ind茅pendants de son conseil d'administration. Les r茅compenses, approuv茅es dans le cadre du Plan d'Incitation 2021 de l'entreprise et conform茅ment 脿 la r猫gle de cotation 635(c)(4) de Nasdaq, consistent en des options d'achat de 205 742 actions ordinaires.
Les options ont 茅t茅 accord茅es le 13 mars 2025, avec un prix d'exercice de 0,93 $ par action, correspondant au prix de cl么ture 脿 la date d'octroi. Le calendrier d'acquisition s'茅tend sur quatre ans, avec un 25% qui acquiert des droits apr猫s la premi猫re ann茅e et les 75% restants qui acqui猫rent des droits en versements mensuels ou trimestriels par la suite, sous r茅serve de certaines conditions d'acc茅l茅ration ou de perte.
Opus Genetics (Nasdaq: IRD), ein biopharmazeutisches Unternehmen im klinischen Stadium, hat die Genehmigung von Aktienverg眉tungen als Anreiz f眉r zwei neue Mitarbeiter durch die unabh盲ngigen Mitglieder des Vorstands bekannt gegeben. Die unter dem Incentive-Plan 2021 des Unternehmens genehmigten Verg眉tungen bestehen aus Optionen zum Kauf von 205.742 Aktien des Stammkapitals.
Die Optionen wurden am 13. M盲rz 2025 gew盲hrt, mit einem Aus眉bungspreis von 0,93 $ pro Aktie, der dem Schlusskurs am Tag der Gew盲hrung entspricht. Der Vesting-Zeitraum erstreckt sich 眉ber vier Jahre, wobei 25% nach dem ersten Jahr und die verbleibenden 75% anschlie脽end in monatlichen oder viertelj盲hrlichen Raten f盲llig werden, vorbehaltlich bestimmter Beschleunigungs- oder Verfallbedingungen.
- None.
- None.
RESEARCH TRIANGLE PARK, N.C., March 19, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biopharmaceutical company developing important new therapies for the treatment of inherited retinal diseases (IRDs) and other ophthalmic disorders (鈥淥pus鈥� or the 鈥淐ompany鈥�), today announced that the independent members of its Board of Directors approved equity awards under the Company鈥檚 2021 Inducement Plan, as amended, as a material inducement to two new employees in connection with the commencement of their employment with the Company effective March 13, 2025. The equity awards were approved in accordance with Nasdaq Listing rule 635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder approved equity plan.
The equity awards were granted in the form of options to purchase an aggregate of 205,742 shares of the Company鈥檚 common stock. The option awards each have an exercise price of
About Opus Genetics
Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and other treatments for ophthalmic disorders. Our pipeline includes adeno-associated virus (AAV)-based investigational gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Our most advanced investigational gene therapy program is designed to address mutations in the LCA5 gene, which encodes the lebercilin protein and is currently being evaluated in a Phase 1/2 open-label, dose-escalation trial, with encouraging early data. Our pipeline also includes BEST1 investigational gene therapy, designed to address mutations in the BEST1 gene, which is associated with retinal degeneration. The pipeline also includes Phentolamine Ophthalmic Solution
Contacts
| Corporate | Investor Relations |
| Nirav Jhaveri CFO [email protected] | Corey Davis, Ph.D. LifeSci Advisors [email protected] |
FAQ
What is the exercise price for Opus Genetics (IRD) inducement stock options granted in March 2025?
How many shares are included in Opus Genetics' (IRD) March 2025 inducement grants?
What is the vesting schedule for Opus Genetics' (IRD) March 2025 inducement stock options?
Under which plan were Opus Genetics' (IRD) March 2025 inducement grants approved?
